A carregar...
Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
For patients with inoperable neuroendocrine tumors (NETs) expressing somatostatin receptors, peptide receptor radionuclide therapy (PRRT) with (177)Lu-[DOTA0-Tyr3]-octreotate ((177)Lu-octreotate) is one of the most promising targeted therapeutic options but it rarely achieves cure. Therefore, differ...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5973847/ https://ncbi.nlm.nih.gov/pubmed/29872498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25266 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|